Statements (61)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:drug
|
gptkbp:activities |
inhibits folate metabolism
|
gptkbp:appointed_by |
vitamin B12
folic acid intravenous injection |
gptkbp:approves |
gptkb:2004
gptkb:FDA |
gptkbp:availability |
prescription only
|
gptkbp:clinical_trial |
Phase II
Phase III |
gptkbp:contraindication |
severe renal impairment
hypersensitivity to pemetrexed |
gptkbp:discovered_by |
gptkb:Eli_Lilly_and_Company
|
gptkbp:dosage_form |
based on renal function
|
gptkbp:excretion |
urine
|
gptkbp:formulation |
lyophilized powder for injection
|
gptkbp:frequency |
every 21 days
|
https://www.w3.org/2000/01/rdf-schema#label |
pemetrexed
|
gptkbp:indication |
gptkb:malignant_pleural_mesothelioma
non-squamous non-small cell lung cancer |
gptkbp:ingredients |
C20 H22 N8 O6 S
|
gptkbp:interacts_with |
other chemotherapy agents
NSAI Ds |
gptkbp:invention |
patented
generic available |
gptkbp:is_atype_of |
L01 B A04
|
gptkbp:is_used_for |
treatment of non-small cell lung cancer
treatment of malignant pleural mesothelioma |
gptkbp:lifespan |
3 to 6 hours
|
gptkbp:marketed_as |
gptkb:Alimta
|
gptkbp:metabolism |
minimal hepatic metabolism
|
gptkbp:pharmacokinetics |
gptkb:fragrance
dose-dependent clearance |
gptkbp:population |
adults
elderly |
gptkbp:price |
high
|
gptkbp:provides_information_on |
combination therapy
ASCO guidelines NCCN guidelines single-agent therapy |
gptkbp:research |
ongoing clinical trials
retrospective studies prospective studies |
gptkbp:research_focus |
biomarker identification
resistance mechanisms combination with immunotherapy |
gptkbp:safety_features |
liver function tests
complete blood count renal function tests |
gptkbp:scholarships |
gptkb:Educational_Institution
financial assistance programs |
gptkbp:side_effect |
gptkb:fandom
fatigue nausea neutropenia |
gptkbp:storage |
room temperature
|
gptkbp:treatment |
symptom relief
improved survival rates |
gptkbp:type_of |
137281-23-3
|
gptkbp:bfsParent |
gptkb:Alimta
|
gptkbp:bfsLayer |
4
|